Suppression of Hypoglycemia by DL-Propranolol in Malignant Insulinoma

I. Blum, D. Aderka, M. Doron, Z. Laron

Research output: Contribution to journalLetterpeer-review


To the Editor: Reports have described the beneficial role of DL-propranolol in relieving hypoglycemic attacks in patients suffering from insulinoma.1 2 3 With the aim of determining whether the glucose-elevating effect of the DL-propranolol was due to the membrane-stabilizing or to beta-adrenergic blocking activity,4 the effect of this drug was compared with that of D-propranolol in a patient with malignant insulinoma (the details of the clinical course of this patient have been described elsewhere3). The patient, who had previously been severely hypoglycemic and suffering from convulsive fits, was symptom free and normoglycemic on DL-propranolol (640 mg per day) for 45 days. No extract is available for articles shorter than 400 words.

Original languageEnglish
Pages (from-to)487
Number of pages1
JournalNew England Journal of Medicine
Issue number9
StatePublished - 31 Aug 1978


Dive into the research topics of 'Suppression of Hypoglycemia by DL-Propranolol in Malignant Insulinoma'. Together they form a unique fingerprint.

Cite this